Physician profile
Mazen Dahan
NPI 1578671830
$2,475.73
in general payments reported to CMS, 2019-2025
30 companies · $315 in 2025
The $315 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $316 · 2021: $236 · 2022: $346 · 2023: $377 · 2024: $287 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $376.73 | 2019-2025 | |
| Corium, LLC | $226.55 | 2022-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $221.70 | 2019-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Ironshore Pharmaceuticals INC. | $207.75 | 2019-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $194.37 | 2020-2022 | |
| Glaxosmithkline, LLC. | $162.85 | 2019-2023 | Bexsero |
| Alk-Abello, INC | $134.52 | 2020-2025 | Odactra, Grastek, Ragwitek |
| Novo Nordisk INC | $108.44 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $103.63 | 2024-2025 | |
| Greer Laboratories, INC. | $78.84 | 2019-2025 | Oralair |
| Genentech USA, INC. | $77.70 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $73.08 | 2022 | |
| Sanofi Pasteur INC. | $61.54 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $49.37 | 2025 | Jornay Pm |
| Alexion Pharmaceuticals, INC. | $40.10 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $34.95 | 2019 | |
| Genzyme Corporation | $32.35 | 2024 | |
| Sobi, INC | $31.09 | 2023 | |
| Cranial Technologies, INC | $30.61 | 2024 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $27.53 | 2025 | Zoryve |
| Celgene Corporation | $24.34 | 2019 | |
| Supernus Pharmaceuticals, INC. | $23.26 | 2025 | Qelbree |
| Pharming Healthcare, INC. | $21.17 | 2024 | Ruconest |
| Qiagen, LLC | $21.13 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $20.40 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $19.94 | 2023 | |
| Bardy Diagnostics, INC. | $19.37 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.76 | 2024 | Bylvay |
| Becton, Dickinson and Company | $16.93 | 2019 | |
| Kaleo, INC. | $16.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Dahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.